Search Prime Grants

U54CA163072

Cooperative Agreement

Overview

Grant Description
Mmc, Vicc & Tsu: Partners in eliminating cancer disparities (2 of 3)
Awardee
Vanderbilt University Medical Center
Funding Goals
TO PROVIDE AN ORGANIZATIONAL FOCUS AND STIMULUS FOR THE HIGHEST QUALITY CANCER RESEARCH THAT EFFECTIVELY PROMOTES INTERDISCIPLINARY CANCER RESEARCH AIMED TOWARD THE ULTIMATE GOAL OF REDUCING CANCER INCIDENCE, MORTALITY AND MORBIDITY. THE CANCER CENTER SUPPORT GRANT (CCSG) PROVIDES THE RESOURCES AND INFRASTRUCTURE TO FACILITATE THE COORDINATION OF INTERDISCIPLINARY PROGRAMS ACROSS A BROAD SPECTRUM OF RESEARCH FROM BASIC LABORATORY RESEARCH TO CLINICAL INVESTIGATION TO POPULATION SCIENCE. THE CCSG SUPPORTS SALARIES FOR SCIENTIFIC LEADERSHIP OF THE CENTER, SHARED RESOURCES FOR FUNDED CENTER INVESTIGATORS, CERTAIN ADMINISTRATIVE COSTS, PLANNING AND EVALUATION, AND DEVELOPMENTAL FUNDS FOR NEW RECRUITMENTS AND FEASIBILITY STUDIES.
Grant Program (CFDA)
93.397 - Cancer Centers Support Grants
Awarding / Funding Agency
National Cancer Institute (NCI) [HHS - NIH]
Place of Performance
Nashville, Tennessee 37232 United States
Geographic Scope
Single Zip Code
Related Opportunity
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional) (PAR-18-767)
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/16 to 08/31/26 and the total obligations have increased 1557% from $1,066,141 to $17,664,563.
Vanderbilt University Medical Center was awarded (2/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities Cooperative Agreement U54CA163072 worth $17,664,563 from National Cancer Institute in September 2011 with work to be completed primarily in Nashville Tennessee United States. The grant has a duration of 15 years and was awarded through assistance program 93.397 Cancer Centers Support Grants. The Cooperative Agreement was awarded through grant opportunity Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 10/4/24

Period of Performance
9/23/11
Start Date
8/31/26
End Date
91.0% Complete

Funding Split
$17.7M
Federal Obligation
$0.0
Non-Federal Obligation
$17.7M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U54CA163072

Subgrant Awards

Disclosed subgrants for U54CA163072

Transaction History

Modifications to U54CA163072

Additional Detail

Award ID FAIN
U54CA163072
SAI Number
U54CA163072-3030467804
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
GYLUH9UXHDX5
Awardee CAGE
7HUA5
Performance District
TN-07
Senators
Marsha Blackburn
Bill Hagerty

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Grants, subsidies, and contributions (41.0) $11,431,566 100%
Modified: 10/4/24